Literature DB >> 23117877

Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate.

Jörg Balss1, Stefan Pusch, Ann-Christin Beck, Christel Herold-Mende, Alwin Krämer, Christian Thiede, Wolfgang Buckel, Claus-Dieter Langhans, Jürgen G Okun, Andreas von Deimling.   

Abstract

Levels of (D)-2-hydroxyglutarate [D2HG, (R)-2-hydroxyglutarate] are increased in some metabolic diseases and in neoplasms with mutations in the isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) genes. Determination of D2HG is of relevance to diagnosis and monitoring of disease. Standard detection methods of D2HG levels are liquid-chromatography-mass spectrometry or gas-chromatography-mass spectrometry. Here we present a rapid, inexpensive and sensitive enzymatic assay for the detection of D2HG levels. The assay is based on the conversion of D2HG to α-ketoglutarate (αKG) in the presence of the enzyme (D)-2-hydroxyglutarate dehydrogenase (HGDH) and nicotinamide adenine dinucleotide (NAD(+)). Determination of D2HG concentration is based on the detection of stoichiometrically generated NADH. The quantification limit of the enzymatic assay for D2HG in tumor tissue is 0.44 μM and in serum 2.77 μM. These limits enable detection of basal D2HG levels in human tumor tissues and serum without IDH mutations. Levels of D2HG in frozen and paraffin-embedded tumor tissues containing IDH mutations or in serum from acute myeloid leukemia patients with IDH mutations are significantly higher and can be easily identified with this assay. In conclusion, the assay presented is useful for differentiating basal from elevated D2HG levels in tumor tissue, serum, urine, cultured cells and culture supernatants.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23117877     DOI: 10.1007/s00401-012-1060-y

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  31 in total

1.  Mutant IDH Sensitizes Gliomas to Endoplasmic Reticulum Stress and Triggers Apoptosis via miR-183-Mediated Inhibition of Semaphorin 3E.

Authors:  Ying Zhang; Stefan Pusch; James Innes; Kastytis Sidlauskas; Matthew Ellis; Joanne Lau; Tedani El-Hassan; Natasha Aley; Francesca Launchbury; Angela Richard-Loendt; Jasper deBoer; Sheng Chen; Lei Wang; Andreas von Deimling; Ningning Li; Sebastian Brandner
Journal:  Cancer Res       Date:  2019-08-07       Impact factor: 12.701

2.  Coupling between d-3-phosphoglycerate dehydrogenase and d-2-hydroxyglutarate dehydrogenase drives bacterial l-serine synthesis.

Authors:  Wen Zhang; Manman Zhang; Chao Gao; Yipeng Zhang; Yongsheng Ge; Shiting Guo; Xiaoting Guo; Zikang Zhou; Qiuyuan Liu; Yingxin Zhang; Cuiqing Ma; Fei Tao; Ping Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-21       Impact factor: 11.205

3.  A vaccine targeting mutant IDH1 induces antitumour immunity.

Authors:  Theresa Schumacher; Lukas Bunse; Stefan Pusch; Felix Sahm; Benedikt Wiestler; Jasmin Quandt; Oliver Menn; Matthias Osswald; Iris Oezen; Martina Ott; Melanie Keil; Jörg Balß; Katharina Rauschenbach; Agnieszka K Grabowska; Isabel Vogler; Jan Diekmann; Nico Trautwein; Stefan B Eichmüller; Jürgen Okun; Stefan Stevanović; Angelika B Riemer; Ugur Sahin; Manuel A Friese; Philipp Beckhove; Andreas von Deimling; Wolfgang Wick; Michael Platten
Journal:  Nature       Date:  2014-06-25       Impact factor: 49.962

4.  Proximity ligation assay evaluates IDH1R132H presentation in gliomas.

Authors:  Lukas Bunse; Theresa Schumacher; Felix Sahm; Stefan Pusch; Iris Oezen; Katharina Rauschenbach; Marina Gonzalez; Gergely Solecki; Matthias Osswald; David Capper; Benedikt Wiestler; Frank Winkler; Christel Herold-Mende; Andreas von Deimling; Wolfgang Wick; Michael Platten
Journal:  J Clin Invest       Date:  2015-01-02       Impact factor: 14.808

5.  Quantitative Analysis of Oncometabolite 2-Hydroxyglutarate.

Authors:  Bi-Feng Yuan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  D-2-Hydroxyglutarate Is Necessary and Sufficient for Isocitrate Dehydrogenase 1 Mutant-Induced MIR148A Promoter Methylation.

Authors:  Tie Li; Christopher D Cox; Byram H Ozer; Nhung T Nguyen; HuyTram N Nguyen; Thomas J Lai; Sichen Li; Fei Liu; Harley I Kornblum; Linda M Liau; Phioanh L Nghiemphu; Timothy F Cloughesy; Albert Lai
Journal:  Mol Cancer Res       Date:  2018-03-15       Impact factor: 5.852

7.  A high-throughput fluorimetric assay for 2-hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor.

Authors:  Adnan Elhammali; Joseph E Ippolito; Lynne Collins; Jan Crowley; Jayne Marasa; David Piwnica-Worms
Journal:  Cancer Discov       Date:  2014-04-16       Impact factor: 39.397

8.  Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia.

Authors:  J Balss; C Thiede; T Bochtler; J G Okun; M Saadati; A Benner; S Pusch; G Ehninger; M Schaich; A D Ho; A von Deimling; A Krämer; C E Heilig
Journal:  Leukemia       Date:  2015-11-19       Impact factor: 11.528

9.  IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity.

Authors:  Sarah Chiang; Britta Weigelt; Huei-Chi Wen; Fresia Pareja; Ashwini Raghavendra; Luciano G Martelotto; Kathleen A Burke; Thais Basili; Anqi Li; Felipe C Geyer; Salvatore Piscuoglio; Charlotte K Y Ng; Achim A Jungbluth; Jörg Balss; Stefan Pusch; Gabrielle M Baker; Kimberly S Cole; Andreas von Deimling; Julie M Batten; Jonathan D Marotti; Hwei-Choo Soh; Benjamin L McCalip; Jonathan Serrano; Raymond S Lim; Kalliopi P Siziopikou; Song Lu; Xiaolong Liu; Tarek Hammour; Edi Brogi; Matija Snuderl; A John Iafrate; Jorge S Reis-Filho; Stuart J Schnitt
Journal:  Cancer Res       Date:  2016-10-20       Impact factor: 13.312

10.  A novel, diffusely infiltrative xenograft model of human anaplastic oligodendroglioma with mutations in FUBP1, CIC, and IDH1.

Authors:  Barbara Klink; Hrvoje Miletic; Daniel Stieber; Peter C Huszthy; Jaime Alberto Campos Valenzuela; Jaime Alberto Campos Valenzuela; Jörg Balss; Jian Wang; Manja Schubert; Per Øystein Sakariassen; Terje Sundstrøm; Anja Torsvik; Mads Aarhus; Rupavathana Mahesparan; Andreas von Deimling; Lars Kaderali; Simone P Niclou; Evelin Schröck; Rolf Bjerkvig; Janice M Nigro
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.